ArticleJournal of clinical medicine2021
Macrolide-Resistant and Macrolide-Sensitive
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Systemic Corticosteroids in Pediatric Community-Acquired Pneumonia: Evidence, Clinical Outcomes, and Phenotype-Based Therapeutic Considerations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Serum Interferon-γ Is Associated With RefractoryJournal of Korean medical science · 2026Article
- East Asia as a sentinel: risk-stratified corticosteroid therapy for paediatric macrolide-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Association between 23S rRNA gene positivity and clinical characteristics in patients with mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Taming the Inflammation: The Role of Corticosteroids in Pediatric Mycoplasma Pneumonia.Children (Basel, Switzerland) · 2026Review
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- Prediction models for refractoryFrontiers in pediatrics · 2026Article
- Clinical Characteristics and Treatment Outcomes of Pediatric Drug-ResistantInfection and drug resistance · 2025Article
- Clinical efficacy of macrolide antibiotics in mycoplasma pneumoniae pneumonia carrying a macrolide-resistant mutation in the 23 S rRNA gene in pediatric patients.BMC infectious diseases · 2024Article
- Macrolide-resistantHeliyon · 2024Article
- The Clinical Significance of Pathogen Loads and Macrolide Resistance Levels for Macrolide-ResistantJournal of inflammation research · 2024Article
- Epidemiology and surveillance implications of community-acquired pneumonia in children.Clinical and experimental pediatrics · 2022Article
- Assessment of variables associated with prolonged admission duration in children with Mycoplasma pneumoniae pneumonia.The clinical respiratory journal · 2022Article
- Risk Factors for the Development of Post-Infectious Bronchiolitis Obliterans in Children: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2022Review
- Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease.Clinical and experimental pediatrics · 2022Article
- The CARDS toxin ofFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We have found that early corticosteroid therapy was effective for reducing morbidity during five Korea-wide epidemics. We evaluated the clinical and laboratory parameters of 56 children who received early corticosteroid treatment for pneumonia that was caused by macrolide-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.